PACTR201904797961340
Recruiting
Phase 3
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: a multicenter, open-label randomized controlled clinical trial
Servicio Madrileno de Salud Fundacion para la Investigacion Biomedica Hospital Universitario 12 de Octubre0 sites624 target enrollmentStarted: April 9, 2019Last updated:
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Servicio Madrileno de Salud Fundacion para la Investigacion Biomedica Hospital Universitario 12 de Octubre
- Enrollment
- 624
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 1 Month(s) to 23 Month(s) (—)
- Sex
- All
Inclusion Criteria
- •1\.Age 28 days to 365 days of age
- •2\.Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60 days of age \=60 breaths per minute and for infants 61 to 365 days of age, \=50 breaths per minute.
- •3\.Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1 or more criteria)
- •a)Chest indrawing with HIV infection
- •b)No improvement with oral treatment.
- •c)One or more danger signs according to WHO
- •\-Central cyanosis or saturation of O2 \<90%
- •\-Severe respiratory distress, e.g. grunting or very severe chest indrawing
- •\-Signs of pneumonia with a general danger sign:
- •\-Unable to drink or breastfeed
Exclusion Criteria
- •1\.Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB\-T prescribed by a physician, at the moment of randomization
- •2\.Known bacteriologically confirmed TB case (at least one biological specimen positive by culture or Xpert MTB/RIF) at the moment of randomization
- •3\.Patient previously treated for TB or currently on treatment for TB
- •4\.Documented evidence of close TB exposure (household contact of a patient with documented TB during the lifetime of the child, or currently receiving TB\-T)
- •5\.Pure wheezers defined as a clear clinical improvement after a bronchodilator test (give a challenge of rapid\-acting inhaled bronchodilator for up to three times 15\-20 minutes apart. Count the breaths and look for chest indrawing again, and then re\-classify)
- •6\.Active malignancies
- •7\.Systemic immunosuppressive medications. Steroids will be considered to be immunosuppressing only if \>2 mg/kg of prednisone or equivalent during \>15 days
- •8\.Evidence of condition other than HIV and pneumonia which precludes, to the judgment of the clinical researcher, enrollment in this trial due to risk for the patient. In case of doubt, the Trial Management Team will be contacted to assess eligibility
- •9\.Less than 2\.5 kg of weight
- •10\.Hb \<6 g/dL in the screening blood test or in a test done in the last 48 hours. Transfusion is permitted to achieve \>6 g/dL if the patient’s state allows it. In case a transfusion is administered, the patient can be enrolled
Investigators
Similar Trials
Completed
Phase 2
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe PneumoniaPneumoniaHIV/AIDSTuberculosisCytomegalovirus InfectionsNCT03915366Hospital Universitario 12 de Octubre563
Recruiting
Not Applicable
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant RecipientsLung DiseasesNCT06494033University of Miami100
Completed
Not Applicable
Effect of ganciclovir eye-drops for corneal endothelitis caused by cytomegalovirus infectioCytomegalovirus coreal endotheliitisCytomegalovirus, Coreal endotheliitisJPRN-jRCTs021180030Tando Toshio10
Completed
Phase 3
CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control groupcongenital cytomegalovirus (CMV)100407921001924310012562NL-OMON41461eids Universitair Medisch Centrum50
Active, not recruiting
Phase 1
Efficacy of antiviral treatment of congenital cytomegalovirus in a non-randomized trial with historical control groupCongenital cytomegalovirus infection.Sensorineural Hearingloss.MedDRA version: 18.0Level: LLTClassification code 10010420Term: Congenital CMV infectionSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-003068-30-NLMC50